Bsafe+ Home Download Template Menu 1 Menu 2 Menu 3 Menu 4 Menu 5

Creating Link

Lookout|What's the result?


 


◆ After the centralized collection of coronary stents, it "dipped" from about 13,000 yuan to about 700 yuan. There was a voice of "not available". Is the supply really insufficient?

◆ Why is artificial joint said to be the most difficult to collect high-value medical consumables? How to overcome the difficulties?

◆ The price of high-value medical consumables is "diving", can the selected varieties be guaranteed for quality and supply?

The original title "The Collective Procurement of High-Value Medical Consumables "The Art of War"

Text | "Liaowang" Newsweek reporter Song Rui Zhang Yuqi

The unreasonable price of high-value medical consumables in China has been gradually squeezed out since 2020. The joint procurement office for high-value medical consumables established in Tianjin (hereinafter referred to as the joint procurement office ) uses the advantages of centralized procurement to adopt "Price" allows companies and patients to achieve a win-win situation, fought two "hard battles" on two high-value medical consumables, coronary stents and artificial joints.

In November 2020, the first national organization of the collection of high-value medical consumables announced the results: the average price of coronary stents "dumped" from about 13,000 yuan to about 700 yuan, a decrease of 93%.

In September 2021, the second batch of national organizations announced the results of the centralized procurement of high-value medical consumables: the average price of artificial hip joints dropped from 35,000 yuan to about 7,000 yuan, and the average price of artificial knee joints dropped from 32,000 yuan to about 5,000 yuan. 82% price reduction.

How can the price of high-value medical consumables achieve "diving"? Can the centralized procurement "art of war" ensure the quality and supply of the selected varieties? On the anniversary of the collection of high-value medical consumables, our reporter will decipher them one by one for you.

▲ On November 5, 2020, the National Organization for the Information Disclosure Conference of Centralized Purchasing of Coronary Stents was held in Tianjin, courtesy of the National Organization for High-Value Medical Consumables Joint Procurement Office

Major operations don’t have to be delayed

"Although it is unpleasant to get sick, I feel that I have made a profit after the operation." Shi Lei, who grew up in Tianjin, the town of cross talk, joked with his surgery payment slip.

On the morning of November 24, 2021, 50-year-old Shi Lei completed the second percutaneous coronary intervention (PCI) at Tianjin First Central Hospital. This time, two coronary stents were installed in his heart.

At the end of March 2021, Shi Lei had a sudden myocardial infarction and caused a coma. After cardiography, his aorta was completely blocked, and he was operated on immediately. After examination, Shi Lei's other blood vessel blockage reached 75%, and the doctor recommended a second operation in half a year.

“Looking at the news for a long time, I learned that starting from January 1, 2021, the new price of coronary stents will be officially implemented. The stent that used to cost 10,000 to 20,000 yuan is now only 700 yuan.” Shi Lei said.

According to Shi Lei, his first operation cost less than 20,000 yuan. "I looked at the bills and there weren't many big numbers on the bill, plus I had medical insurance and commercial insurance, so I could hardly spend any money. Don't worry about the cost of the second operation, and I feel good now."

The reporter noticed that on the electrocardiogram monitor next to Shi Lei's bed, the real-time output waveform line recorded his steady and powerful heartbeat. Shi Lei rolled up his cuff and showed the reporter the surgical wound on his right wrist. "This wound is the size of a soybean, and the wound healed very well during the first operation. You can't see it unless you look closely."

Lu Chengzhi, chief physician of the Department of Cardiology, Tianjin First Central Hospital, said: “When the price of coronary stents was not reduced before, I had encountered patients who gave up because they couldn’t perform surgery, and patients who wanted to avoid expenses after installing coronary stents. After the collection of coronary stents, such cases rarely happen, and the common people save a lot of treatment costs."

In early November 2021, Xing Hua from Jilin Province implanted 3 coronary stents in his heart due to a heart attack. "I know my heart’s old problems. In the past, doctors also recommended me to do coronary stent surgery, but a coronary stent cost more than 20,000 yuan . Some hospitals asked me to prepare 180,000 yuan for medical expenses. This is too expensive. I couldn't bear it after thinking about it, so I kept dragging on." 49-year-old Xing Hua sighed.

"This time I was admitted to the hospital for a sudden myocardial infarction. I didn't expect that a coronary stent cost only a few hundred yuan . I did the operation without thinking about it. The operation fee plus the hospitalization fee was only 30,000 yuan . I recovered a day after the operation. It feels good." Xing Hua sighed: "The price of the original major surgery has dropped, and ordinary people can afford it. Heart problems can kill people at any time. It's better now, and patients with financial constraints don't have to delay and delay."

Gao Xue, head of the centralized procurement team of the Joint Procurement Office, introduced that among the 10 products selected for coronary stents, the highest price was 798 yuan and the lowest price was 469 yuan, including 7 products from 6 domestic companies and 3 products from 2 import companies. .

According to data provided by the United Procurement Office, from January to November 2021, medical institutions used a total of 1.3114 million selected products, which is a 33.46% increase compared to the number of drug-loaded coronary stents used in the same period in 2020 (982,600) before centralized procurement. The total amount used in the first 11 months has exceeded the national annual contracted purchase volume (1.07 million).

"We have brought together the procurement requirements of medical institutions across the country. A clear procurement volume can significantly reduce the cost of enterprises in the circulation and sales links, thereby freeing up room for price reductions. In order to maintain or expand the original market share, production companies will spontaneously Reduce prices to achieve the effect of'quantity for price'. " Gao Xue said.

“Centralized procurement of high-value medical consumables has effectively reduced the burden on patients for medical treatment, and allowed the masses to enjoy the reform dividends.” said Li Guotian, secretary of the party group and director of the Tianjin Medical Security Bureau.

It is not only the patients who benefited—the price of high-value medical consumables was reduced, the pressure on the medical insurance fund pool was reduced, and doctors with scalpels also increased a lot of "sunshine income."

"After centralized procurement squeezed out the gray costs in the circulation link, manufacturers, distribution companies, and medical institutions will return to normal and equal purchase and sales relationships. Some provinces with lower surgical fees will raise their fees, and apply medical insurance payment balance retention and payment methods. Reform and other mechanisms to increase the "sunshine income" of medical staff in relevant departments under stable workload conditions." said Zhang Tiejun, director of the Joint Procurement Office and deputy director of the Tianjin Medical Security Bureau.

How to avoid gathering "press the gourd and float the scoop"

The benefits of the drastic reduction in the price of coronary stents have quickly been recognized by the people. The "national team" has continued to make accurate artificial joints without stopping. It is expected that patients across the country will gradually use the selected products after the price reduction after March 2022.

It is understood that from coronary stents to artificial joints, the "art of war" of the "national team" is not simply copied. The principle of "one product, one policy" came into being.

"Orthopedic consumables is the category with the highest market share of high-value medical consumables. Due to the complexity of technical classification and combination, this type of consumables has long been a difficult point in centralized procurement." said Zhang Minghui, Business Division of United Procurement.

In order to gnaw this hard bone, after conducting extensive research on manufacturing companies, medical institutions, clinical use, international market prices, etc., Joint Procurement Designed a targeted procurement plan based on the characteristics of artificial joints, and tailored appropriate centralized procurement rules. .

It is understood that artificial joints are artificial joint prostheses that are used to replace the original hip and knee joints of the human body that need to be replaced due to end-stage hip and knee diseases such as osteonecrosis, comminuted fractures, osteoarthropathy, and bone tumors.

"Artificial total hip joints are generally composed of 4 parts, and artificial knee joints are generally composed of 3 parts. Hip and knee joint prostheses are made of different materials according to different parts." Zhang Minghui said, compared with a piece counted as a unit Centralized collection of coronary stents, and the difficulty of centralized collection of artificial joints has doubled.

In accordance with the principle of "combination of recruitment and procurement", after analyzing massive procurement and usage data, Joint Procurement will combine multiple main components required for clinical complete surgery into a product system to implement procurement, avoiding shortages of some necessary components due to unsuccessful bids, or partial components Because it is not included in the centralized procurement, the price has been increased wildly to ensure the integrity and safety of clinical treatment.

According to Ding Yilei, Director of the Department of Medical Price and Bidding and Purchasing of the National Medical Security Administration, the system-based quotation can avoid the situation of "pressing the gourd and lifting the scoop" and reducing the overall cost of patients.

At the National Organized Artificial Joint Centralized Purchase Declaration Information Disclosure Conference held in September 2021, 44 of the 48 companies that participated in the election were selected, with a winning rate of 92%. Both domestic and foreign companies have products to be selected, including well-known companies commonly used by medical institutions and emerging companies, taking into account market stability and vitality.

In Ding Yilei's view, the results of this election are basically in line with expectations. "The intended purchase of selected products accounted for more than 80% of the total intended purchase of medical institutions, indicating that this centralized procurement has achieved a high degree of matching with clinical actual needs while reducing the falsely high prices."

The United Procurement Office calculated the demand for artificial joints in 5804 medical institutions across the country and found that the intention to purchase artificial joints in the first year was 540,000 sets, accounting for 90% of the total demand. "Through a comparative analysis of the relevant cost situation in the previous period, this centralized procurement not only reduced the falsely high price of artificial joints, but also gave the company a certain amount of profit and development space, and achieved a balance in many aspects." Ding Yilei said.

According to estimates by the National Medical Insurance Administration, based on the 2020 purchase price, the purchase amount of artificial hip and knee joints in public medical institutions is about 20 billion yuan. It is estimated that 16 billion yuan will be saved, and more than 500,000 joint replacement patients will benefit significantly each year.

How to guarantee the quality and supply of the selected varieties

As the first "test water" country to purchase high-value medical consumables, in the implementation of new prices for coronary stents, there have been "incomplete types of coronary stents", "previously no money for surgery, now there is money but no stents" etc. sound.

In response, the United Procurement Office immediately investigated and gave the overall situation of the country: From January to November 2021, the selected enterprises have supplied 2,600,700 selected stents from the factory, which is more than 2.42 times of the annual contracted purchase volume, which is 1.98 of the actual usage by the hospital. Times.

This means that from a national perspective, the supply of coronary stents is higher than the actual amount used. There are sufficient stocks of coronary stents of various specifications, and there is no “out of supply” situation of coronary stents in general.

"Before the centralized procurement, the price of coronary stents was falsely high, which supported the delivery companies to provide on-call, anytime replenishment and gift-giving'nanny-style' services. After the price of centralized procurement of coronary stents fell, the logistics cost was greatly reduced. Modern technologies such as efficiency and increased accuracy are "digested", and production companies, distribution companies, and medical institutions continue to improve supply efficiency in the course of running-in. " Gao Xue said.

At the same time, the Joint Procurement Office, in conjunction with relevant departments, instructs medical institutions to strengthen procurement and inventory management capacity building, and improve the efficiency of information transmission and procurement operations. It is reported that the United Procurement Office has specially developed online coronary stent production capacity and inventory reporting functions to facilitate timely understanding of the inventory of selected products and predict shortages.

According to the Tianjin First Central Hospital, the hospital has strengthened the refined management of high-value medical consumables in the hospital, including stocking, use, inventory, and replenishment. "Our cardiology department will complete more than 1,200 PCI surgeries throughout 2020. After the new price is implemented, more than 1,600 PCI operations have been completed since 2021." Apply for an increase, and get the incremental supplement in time, and the supply as a whole can be met."

Recently, Xia Qun, director of the Department of Orthopedics at Tianjin First Central Hospital, immediately asked his colleagues in the cardiology department about the experience of applying product dosages in the work of filling in the procurement requirements of medical institutions for the centralized procurement of artificial joints.

In order to avoid the situation that the main products that did not win the bid and affect the follow-up use of the hospital, he originally decided to "put the eggs in different baskets"-to report for different joint models. Xia Qun feels more relieved when he understands that the centralized procurement of artificial joints is based on the experience of centralized procurement of coronary stents, and there is a margin allocation link.

"With this link, the hospital does not need to be too nervous when reporting the amount in the early stage, and can select some products that our doctors can use easily from the winning companies and products according to the follow-up use situation during the'surplus allocation'. Doctors hope to use more Familiar products are like driving a familiar car, and the patients will feel more at ease when they know how much the "gas pedal" is stepped on." Xia Qun said.

Different from coronary stent surgery, artificial joint replacement has a strong demand for accompanying services such as surgical table, logistics distribution, warehouse management, and supporting tools. In addition to basic services such as product distribution and disinfection, product usage guidance at the surgical site is also required to ensure the accuracy of the application of each component.

Zhang Tiejun said that in order to ensure that clinical use is not affected, the centralized procurement of artificial joints requires companies to clarify the price of the accompanying service and include the price of the accompanying service in the calculation of the bid price. This not only improves the transparency of the product price composition, but also ensures that the selected products can provide comprehensive accompanying services. "If the disinfection process is clearly borne by the medical department, the cost of disinfection will not be added to the product price." Zhang Tiejun said.

After the price of centralized procurement of artificial joints has plunged, the "difficulty coefficient" of the running-in of production, distribution and medical institutions has doubled. Many people worry that companies will squeeze the accompanying services and affect subsequent supply and use.

In order to ensure supply, the Joint Procurement Office stipulates that when companies declare products, they can freely choose to supply the country or only part of the city, to ensure that the company chooses the supply area according to its own ability and historical sales scope, and can ensure sufficient and timely supply after the selection.

In response to the patient's most concerned "price reduction, no quality reduction" issue, Gao Xue said that companies must ensure the quality of the products they supply, and any adjustments to raw materials and production processes must be submitted to the State Food and Drug Administration for approval and strict inspections. As far as coronary stents are concerned, the drug regulatory department conducts full-cycle quality supervision on the production, circulation, and use of coronary stents. "Each coronary stent has an identification code, which can be traced and monitored from production to use." Gao Xue said.

In order to do a good job in the implementation of artificial joints, the Joint Procurement Office will establish a registration system and develop a registration system for medical consumables (artificial joints) in China Medical Insurance. The comrade in charge of the information work of the United Procurement Office, Chen Yuxiang, said: “The system will collect patient information, surgeon information, product usage information and surgery-related information, establish patient files, aggregate usage data, and facilitate product quality supervision and accountability.”

"What the common people are concerned about is the direction of our efforts. In the future, we will carry out centralized procurement of high-value medical consumables produced by many companies with larger clinical usage, higher purchase amount, more mature clinical use, and Changing prices will benefit the people." Zhang Tiejun said.

Search This Blog

Lookout|What's the result?

 


◆ After the centralized collection of coronary stents, it "dipped" from about 13,000 yuan to about 700 yuan. There was a voice of "not available". Is the supply really insufficient?

◆ Why is artificial joint said to be the most difficult to collect high-value medical consumables? How to overcome the difficulties?

◆ The price of high-value medical consumables is "diving", can the selected varieties be guaranteed for quality and supply?

The original title "The Collective Procurement of High-Value Medical Consumables "The Art of War"

Text | "Liaowang" Newsweek reporter Song Rui Zhang Yuqi

The unreasonable price of high-value medical consumables in China has been gradually squeezed out since 2020. The joint procurement office for high-value medical consumables established in Tianjin (hereinafter referred to as the joint procurement office ) uses the advantages of centralized procurement to adopt "Price" allows companies and patients to achieve a win-win situation, fought two "hard battles" on two high-value medical consumables, coronary stents and artificial joints.

In November 2020, the first national organization of the collection of high-value medical consumables announced the results: the average price of coronary stents "dumped" from about 13,000 yuan to about 700 yuan, a decrease of 93%.

In September 2021, the second batch of national organizations announced the results of the centralized procurement of high-value medical consumables: the average price of artificial hip joints dropped from 35,000 yuan to about 7,000 yuan, and the average price of artificial knee joints dropped from 32,000 yuan to about 5,000 yuan. 82% price reduction.

How can the price of high-value medical consumables achieve "diving"? Can the centralized procurement "art of war" ensure the quality and supply of the selected varieties? On the anniversary of the collection of high-value medical consumables, our reporter will decipher them one by one for you.

▲ On November 5, 2020, the National Organization for the Information Disclosure Conference of Centralized Purchasing of Coronary Stents was held in Tianjin, courtesy of the National Organization for High-Value Medical Consumables Joint Procurement Office

Major operations don’t have to be delayed

"Although it is unpleasant to get sick, I feel that I have made a profit after the operation." Shi Lei, who grew up in Tianjin, the town of cross talk, joked with his surgery payment slip.

On the morning of November 24, 2021, 50-year-old Shi Lei completed the second percutaneous coronary intervention (PCI) at Tianjin First Central Hospital. This time, two coronary stents were installed in his heart.

At the end of March 2021, Shi Lei had a sudden myocardial infarction and caused a coma. After cardiography, his aorta was completely blocked, and he was operated on immediately. After examination, Shi Lei's other blood vessel blockage reached 75%, and the doctor recommended a second operation in half a year.

“Looking at the news for a long time, I learned that starting from January 1, 2021, the new price of coronary stents will be officially implemented. The stent that used to cost 10,000 to 20,000 yuan is now only 700 yuan.” Shi Lei said.

According to Shi Lei, his first operation cost less than 20,000 yuan. "I looked at the bills and there weren't many big numbers on the bill, plus I had medical insurance and commercial insurance, so I could hardly spend any money. Don't worry about the cost of the second operation, and I feel good now."

The reporter noticed that on the electrocardiogram monitor next to Shi Lei's bed, the real-time output waveform line recorded his steady and powerful heartbeat. Shi Lei rolled up his cuff and showed the reporter the surgical wound on his right wrist. "This wound is the size of a soybean, and the wound healed very well during the first operation. You can't see it unless you look closely."

Lu Chengzhi, chief physician of the Department of Cardiology, Tianjin First Central Hospital, said: “When the price of coronary stents was not reduced before, I had encountered patients who gave up because they couldn’t perform surgery, and patients who wanted to avoid expenses after installing coronary stents. After the collection of coronary stents, such cases rarely happen, and the common people save a lot of treatment costs."

In early November 2021, Xing Hua from Jilin Province implanted 3 coronary stents in his heart due to a heart attack. "I know my heart’s old problems. In the past, doctors also recommended me to do coronary stent surgery, but a coronary stent cost more than 20,000 yuan . Some hospitals asked me to prepare 180,000 yuan for medical expenses. This is too expensive. I couldn't bear it after thinking about it, so I kept dragging on." 49-year-old Xing Hua sighed.

"This time I was admitted to the hospital for a sudden myocardial infarction. I didn't expect that a coronary stent cost only a few hundred yuan . I did the operation without thinking about it. The operation fee plus the hospitalization fee was only 30,000 yuan . I recovered a day after the operation. It feels good." Xing Hua sighed: "The price of the original major surgery has dropped, and ordinary people can afford it. Heart problems can kill people at any time. It's better now, and patients with financial constraints don't have to delay and delay."

Gao Xue, head of the centralized procurement team of the Joint Procurement Office, introduced that among the 10 products selected for coronary stents, the highest price was 798 yuan and the lowest price was 469 yuan, including 7 products from 6 domestic companies and 3 products from 2 import companies. .

According to data provided by the United Procurement Office, from January to November 2021, medical institutions used a total of 1.3114 million selected products, which is a 33.46% increase compared to the number of drug-loaded coronary stents used in the same period in 2020 (982,600) before centralized procurement. The total amount used in the first 11 months has exceeded the national annual contracted purchase volume (1.07 million).

"We have brought together the procurement requirements of medical institutions across the country. A clear procurement volume can significantly reduce the cost of enterprises in the circulation and sales links, thereby freeing up room for price reductions. In order to maintain or expand the original market share, production companies will spontaneously Reduce prices to achieve the effect of'quantity for price'. " Gao Xue said.

“Centralized procurement of high-value medical consumables has effectively reduced the burden on patients for medical treatment, and allowed the masses to enjoy the reform dividends.” said Li Guotian, secretary of the party group and director of the Tianjin Medical Security Bureau.

It is not only the patients who benefited—the price of high-value medical consumables was reduced, the pressure on the medical insurance fund pool was reduced, and doctors with scalpels also increased a lot of "sunshine income."

"After centralized procurement squeezed out the gray costs in the circulation link, manufacturers, distribution companies, and medical institutions will return to normal and equal purchase and sales relationships. Some provinces with lower surgical fees will raise their fees, and apply medical insurance payment balance retention and payment methods. Reform and other mechanisms to increase the "sunshine income" of medical staff in relevant departments under stable workload conditions." said Zhang Tiejun, director of the Joint Procurement Office and deputy director of the Tianjin Medical Security Bureau.

How to avoid gathering "press the gourd and float the scoop"

The benefits of the drastic reduction in the price of coronary stents have quickly been recognized by the people. The "national team" has continued to make accurate artificial joints without stopping. It is expected that patients across the country will gradually use the selected products after the price reduction after March 2022.

It is understood that from coronary stents to artificial joints, the "art of war" of the "national team" is not simply copied. The principle of "one product, one policy" came into being.

"Orthopedic consumables is the category with the highest market share of high-value medical consumables. Due to the complexity of technical classification and combination, this type of consumables has long been a difficult point in centralized procurement." said Zhang Minghui, Business Division of United Procurement.

In order to gnaw this hard bone, after conducting extensive research on manufacturing companies, medical institutions, clinical use, international market prices, etc., Joint Procurement Designed a targeted procurement plan based on the characteristics of artificial joints, and tailored appropriate centralized procurement rules. .

It is understood that artificial joints are artificial joint prostheses that are used to replace the original hip and knee joints of the human body that need to be replaced due to end-stage hip and knee diseases such as osteonecrosis, comminuted fractures, osteoarthropathy, and bone tumors.

"Artificial total hip joints are generally composed of 4 parts, and artificial knee joints are generally composed of 3 parts. Hip and knee joint prostheses are made of different materials according to different parts." Zhang Minghui said, compared with a piece counted as a unit Centralized collection of coronary stents, and the difficulty of centralized collection of artificial joints has doubled.

In accordance with the principle of "combination of recruitment and procurement", after analyzing massive procurement and usage data, Joint Procurement will combine multiple main components required for clinical complete surgery into a product system to implement procurement, avoiding shortages of some necessary components due to unsuccessful bids, or partial components Because it is not included in the centralized procurement, the price has been increased wildly to ensure the integrity and safety of clinical treatment.

According to Ding Yilei, Director of the Department of Medical Price and Bidding and Purchasing of the National Medical Security Administration, the system-based quotation can avoid the situation of "pressing the gourd and lifting the scoop" and reducing the overall cost of patients.

At the National Organized Artificial Joint Centralized Purchase Declaration Information Disclosure Conference held in September 2021, 44 of the 48 companies that participated in the election were selected, with a winning rate of 92%. Both domestic and foreign companies have products to be selected, including well-known companies commonly used by medical institutions and emerging companies, taking into account market stability and vitality.

In Ding Yilei's view, the results of this election are basically in line with expectations. "The intended purchase of selected products accounted for more than 80% of the total intended purchase of medical institutions, indicating that this centralized procurement has achieved a high degree of matching with clinical actual needs while reducing the falsely high prices."

The United Procurement Office calculated the demand for artificial joints in 5804 medical institutions across the country and found that the intention to purchase artificial joints in the first year was 540,000 sets, accounting for 90% of the total demand. "Through a comparative analysis of the relevant cost situation in the previous period, this centralized procurement not only reduced the falsely high price of artificial joints, but also gave the company a certain amount of profit and development space, and achieved a balance in many aspects." Ding Yilei said.

According to estimates by the National Medical Insurance Administration, based on the 2020 purchase price, the purchase amount of artificial hip and knee joints in public medical institutions is about 20 billion yuan. It is estimated that 16 billion yuan will be saved, and more than 500,000 joint replacement patients will benefit significantly each year.

How to guarantee the quality and supply of the selected varieties

As the first "test water" country to purchase high-value medical consumables, in the implementation of new prices for coronary stents, there have been "incomplete types of coronary stents", "previously no money for surgery, now there is money but no stents" etc. sound.

In response, the United Procurement Office immediately investigated and gave the overall situation of the country: From January to November 2021, the selected enterprises have supplied 2,600,700 selected stents from the factory, which is more than 2.42 times of the annual contracted purchase volume, which is 1.98 of the actual usage by the hospital. Times.

This means that from a national perspective, the supply of coronary stents is higher than the actual amount used. There are sufficient stocks of coronary stents of various specifications, and there is no “out of supply” situation of coronary stents in general.

"Before the centralized procurement, the price of coronary stents was falsely high, which supported the delivery companies to provide on-call, anytime replenishment and gift-giving'nanny-style' services. After the price of centralized procurement of coronary stents fell, the logistics cost was greatly reduced. Modern technologies such as efficiency and increased accuracy are "digested", and production companies, distribution companies, and medical institutions continue to improve supply efficiency in the course of running-in. " Gao Xue said.

At the same time, the Joint Procurement Office, in conjunction with relevant departments, instructs medical institutions to strengthen procurement and inventory management capacity building, and improve the efficiency of information transmission and procurement operations. It is reported that the United Procurement Office has specially developed online coronary stent production capacity and inventory reporting functions to facilitate timely understanding of the inventory of selected products and predict shortages.

According to the Tianjin First Central Hospital, the hospital has strengthened the refined management of high-value medical consumables in the hospital, including stocking, use, inventory, and replenishment. "Our cardiology department will complete more than 1,200 PCI surgeries throughout 2020. After the new price is implemented, more than 1,600 PCI operations have been completed since 2021." Apply for an increase, and get the incremental supplement in time, and the supply as a whole can be met."

Recently, Xia Qun, director of the Department of Orthopedics at Tianjin First Central Hospital, immediately asked his colleagues in the cardiology department about the experience of applying product dosages in the work of filling in the procurement requirements of medical institutions for the centralized procurement of artificial joints.

In order to avoid the situation that the main products that did not win the bid and affect the follow-up use of the hospital, he originally decided to "put the eggs in different baskets"-to report for different joint models. Xia Qun feels more relieved when he understands that the centralized procurement of artificial joints is based on the experience of centralized procurement of coronary stents, and there is a margin allocation link.

"With this link, the hospital does not need to be too nervous when reporting the amount in the early stage, and can select some products that our doctors can use easily from the winning companies and products according to the follow-up use situation during the'surplus allocation'. Doctors hope to use more Familiar products are like driving a familiar car, and the patients will feel more at ease when they know how much the "gas pedal" is stepped on." Xia Qun said.

Different from coronary stent surgery, artificial joint replacement has a strong demand for accompanying services such as surgical table, logistics distribution, warehouse management, and supporting tools. In addition to basic services such as product distribution and disinfection, product usage guidance at the surgical site is also required to ensure the accuracy of the application of each component.

Zhang Tiejun said that in order to ensure that clinical use is not affected, the centralized procurement of artificial joints requires companies to clarify the price of the accompanying service and include the price of the accompanying service in the calculation of the bid price. This not only improves the transparency of the product price composition, but also ensures that the selected products can provide comprehensive accompanying services. "If the disinfection process is clearly borne by the medical department, the cost of disinfection will not be added to the product price." Zhang Tiejun said.

After the price of centralized procurement of artificial joints has plunged, the "difficulty coefficient" of the running-in of production, distribution and medical institutions has doubled. Many people worry that companies will squeeze the accompanying services and affect subsequent supply and use.

In order to ensure supply, the Joint Procurement Office stipulates that when companies declare products, they can freely choose to supply the country or only part of the city, to ensure that the company chooses the supply area according to its own ability and historical sales scope, and can ensure sufficient and timely supply after the selection.

In response to the patient's most concerned "price reduction, no quality reduction" issue, Gao Xue said that companies must ensure the quality of the products they supply, and any adjustments to raw materials and production processes must be submitted to the State Food and Drug Administration for approval and strict inspections. As far as coronary stents are concerned, the drug regulatory department conducts full-cycle quality supervision on the production, circulation, and use of coronary stents. "Each coronary stent has an identification code, which can be traced and monitored from production to use." Gao Xue said.

In order to do a good job in the implementation of artificial joints, the Joint Procurement Office will establish a registration system and develop a registration system for medical consumables (artificial joints) in China Medical Insurance. The comrade in charge of the information work of the United Procurement Office, Chen Yuxiang, said: “The system will collect patient information, surgeon information, product usage information and surgery-related information, establish patient files, aggregate usage data, and facilitate product quality supervision and accountability.”

"What the common people are concerned about is the direction of our efforts. In the future, we will carry out centralized procurement of high-value medical consumables produced by many companies with larger clinical usage, higher purchase amount, more mature clinical use, and Changing prices will benefit the people." Zhang Tiejun said.

Comments


Ad Blocker Detected

Please turn off your adBlock because only ads make us excited, Thank you !!!